Nicolas Boudou

Showing 1-6 of 6 articles

Author Nicolas Boudou

EuroCTO Club 2018 meeting: “Experts Live” in Toulouse

Boudou N, Avran A, Garbo R, Lefèvre T, Hildick-Smith D, Reifart N, Galassi A, Mattesini A, Dini C, Brilakis E, Yamane M, Sianos G, Mashayekhi K, Karmpaliotis D, DeMartini T, Werner G, Di Mario C

April 5, 2019 | 10.4244/EIJV14I18A319

Author Thomas Chollet

Interventions for valvular disease

Propensity-matched comparison of clinical outcomes after transaortic versus transfemoral aortic valve replacement

Chollet T, Marcheix B, Boudou N, Elbaz M, Campelo-Parada F, Bataille V, Bouisset F, Lairez O, Porterie J, Galinier M, Carrie D, Lhermusier T

September 20, 2018 | 10.4244/EIJ-D-18-00168

Author Alexander Bufe

The Experts “Live” Workshop of the EuroCTO Club 2017, Berlin

Bufe A, Di Mario C, Landmesser U, Gessner M, Sianos G, Garbo R, Dini C, Lauer B, Boudou N, Grancini L, Avran A, Lauten A, Mashayekhi K, Hildick-Smith D, Escaned J, Buettner H, Reifart N, Lapp H, Galassi A, Werner G

April 20, 2018 | 10.4244/EIJV13I17A324

Author Anouska Moynagh

Two-year outcomes of everolimus vs. paclitaxel-eluting stent for the treatment of unprotected left main lesions: a propensity score matching comparison of patients included in the French Left Main Taxus (FLM Taxus) and the LEft MAin Xience (LEMAX) registries

Moynagh A, Salvatella N, Harb T, Darremont O, Boudou N, Dumonteil N, Lefèvre T, Carrie D, Louvard Y, Leymarie J-L, Chevalier B, Morice M, Garot P

August 23, 2013 | 10.4244/EIJV9I4A74

Author Neus Salvatella

Unprotected left main stenting with a second-generation drug-eluting stent: one-year outcomes of the LEMAX Pilot study

Salvatella N, Morice M, Darremont O, Tafflet M, Garot P, Leymarie J, Chevalier B, Lefèvre T, Louvard Y, Boudou N, Dumonteil N, Carrié D

October 28, 2011 | 10.4244/EIJV7I6A111

Author Nicolas Boudou

Long-term clinical outcome after percutaneous coronary interventions in the elderly: results for 512 consecutive patients

Boudou N, Roncalli J, Lhermusier T, Moudens G, Celse D, Fourcade J, Elbaz M, Baixas C, Puel J, Carrie D

January 20, 2008

1

Latest news

Antiplatelet strategies for complex PCI, are all DES equal at 10-year follow-up? cost-effectiveness of TAVR…find all the answers in the new issue

(Intravascular lithotripsy (3.5 mm Shockwave; left), followed by balloon dilatation (4.0 mm NC; right))

December 6, 2019

Discover 5 new trials: GALILEO, CONDI-2/ERIC-PCI, EVOLUTE II-5 years, SCOPE and Excel 5 years

(The Trials book is supported by Biotronik)

December 13, 2019

New this week: A Dose-response Meta Analysis, stroke after MitraClip and more

December 10, 2019

The challenge of innovation for the (interventional?) cardiology world

December 6, 2019

Guidance Papers

Guidelines, consensus & position papers

2019 – A leap year for valvular heart disease

(Course directors PCR London Valves 2019)

November 15, 2019

Last week's JAA's: EXTREME Study, Stent Optimization and more

December 3, 2019

Coronary

Valvular disease

Heart failure

Peripheral

Hypertension

Stroke